Target Information

Target General Infomation
Target ID
T13017
Former ID
TTDI02170
Target Name
Syndecan-1
Gene Name
SDC1
Synonyms
CD138; SYND1; SDC1
Target Type
Clinical Trial
Disease Multiple myeloma [ICD9: 203; ICD10: C90]
Function
Cell surface proteoglycan that bears both heparan sulfate and chondroitin sulfate and that links the cytoskeleton to the interstitial matrix.
BioChemical Class
Syndecan proteoglycan
UniProt ID
P18827
Sequence
MRRAALWLWLCALALSLQPALPQIVATNLPPEDQDGSGDDSDNFSGSGAGALQDITLSQQ
TPSTWKDTQLLTAIPTSPEPTGLEATAASTSTLPAGEGPKEGEAVVLPEVEPGLTAREQE
ATPRPRETTQLPTTHLASTTTATTAQEPATSHPHRDMQPGHHETSTPAGPSQADLHTPHT
EDGGPSATERAAEDGASSQLPAAEGSGEQDFTFETSGENTAVVAVEPDRRNQSPVDQGAT
GASQGLLDRKEVLGGVIAGGLVGLIFAVCLVGFMLYRMKKKDEGSYSLEEPKQANGGAYQ
KPTKQEEFYA
Drugs and Mode of Action
Drug(s) BT-062 Drug Info Phase 1/2 Multiple myeloma [522830]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
Pathway Interaction Database Beta3 integrin cell surface interactions
Integrins in angiogenesis
Proteoglycan syndecan-mediated signaling events
Syndecan-1-mediated signaling events
Beta5 beta6 beta7 and beta8 integrin cell surface interactions
References
Ref 522830ClinicalTrials.gov (NCT01001442) Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 530195The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15;15(12):4028-37.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.